Atopic dermatitis, commonly known as eczema, is a chronic inflammatory dermatosis that
can affect individuals from infancy to adulthood. Also referred to as “the itch that rashes” …

Atopic dermatitis (AD) is a clinically defined, highly pruritic, chronic inflammatory skin
disease of children and adults. The diagnosis is made using evaluated clinical criteria …

Background Severe atopic dermatitis (AD) has a high unmet need for effective and safe
therapeutics. In early-phase trials, dupilumab, a fully human mAb targeting IL-4 receptor α …

Atopic dermatitis (AD) is a common inflammatory skin disease characterized by intense
pruritus and recurrent eczematous lesions that significantly impair quality of life. It is a …

Background Dupilumab is an anti‐IL‐4Rα antibody used in the treatment of patients with
moderate‐to‐severe atopic dermatitis (msAD). This study explored the potential benefit of …

In the past, atopic dermatitis was considered as a polyfactorial disease. In reality, that meant
that its pathophysiogeny was not understood. Nowadays, atopic dermatitis appears to be …

Introduction: Current treatment options for moderate-to-severe atopic dermatitis (AD) are
limited and have potentially dangerous side effects. Dupilumab is a novel monoclonal …

Background Management of moderate‐to‐severe atopic dermatitis (AD) frequently requires
treatment with systemic therapies. Dupilumab is the first biological agent approved for …

Although atopic dermatitis (AD) classically presents as eczematous, pruritic plaques in the
flexural regions of children, AD can present with several morphologies and distributions that …

Atopic dermatitis (AD) is a highly pruritic, chronic inflammatory skin disease. The diagnosis
is made using evaluated clinical criteria. Disease activity and burden are best measured …